WO2026088163 - COMPOSITIONS OF ENGINEERED CYTOKINE EXPRESSING CELLS AND METHODS OF USE THEREOF
National phase entry is expected:
Publication Number
WO/2026/088163
Publication Date
30.04.2026
International Application No.
PCT/IB2025/060870
International Filing Date
24.10.2025
Title **
[English]
COMPOSITIONS OF ENGINEERED CYTOKINE EXPRESSING CELLS AND METHODS OF USE THEREOF
[French]
COMPOSITIONS DE CELLULES EXPRIMANT DES CYTOKINES MODIFIÉES ET LEURS PROCÉDÉS D'UTILISATION
Applicants **
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventors
WANG, Yana
ZHU, Zengrong
LI, Shan
Priority Data
63/712,126
25.10.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3716 | |
| EPO | Filing, Examination, Granting | 27527 | |
| Japan | Filing, Examination, Granting | 3177 | |
| South Korea | Filing, Examination, Granting | 4005 | |
| USA | Filing, Examination, Granting | 11790 |
Total:
50,215
Contact Us
Abstract[English]
Provided herein is an immune cell expressing a recombinant IL-2 or IL-2 mutein, wherein the immune cell is a natural killer cells (e.g., a cord blood derived NK (CB-NK) cell) or a γδ T cell, and wherein the IL-2 mutein has reduced binding to IL2 receptor (IL2R) (e.g., IL2Rβ). These immune cells can also be used in conjunction with cells genetically engineered with chimeric antigen receptors (CARs). Also provided are methods of modulating immune function by administering said immune cell, and methods of treating cancer, for example, acute myeloid leukemia.[French]
La présente invention concerne une cellule immunitaire exprimant une IL-2 recombinante ou une mutéine d'IL-2, la cellule immunitaire étant une cellule tueuse naturelle (par exemple, une cellule NK dérivée de sang de cordon ombilical (CB-NK)) ou une cellule T γδ, et la mutéine d'IL-2 présentant une liaison réduite au récepteur de l'IL2 (IL2R) (par exemple, IL2Rβ). Ces cellules immunitaires peuvent également être utilisées conjointement avec des cellules génétiquement modifiées avec des récepteurs antigéniques chimériques (CAR). L'invention concerne également des procédés de modulation de la fonction immunitaire par administration de ladite cellule immunitaire, et des procédés de traitement d'un cancer, par exemple de la leucémie myéloïde aiguë.